Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2022
Reporting Period: Quarterly period ended June 30, 2022
This filing serves as a notification that the company issued a press release and an earnings presentation regarding its financial results for the second quarter of 2022. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) rather than within the body of this 8-K form.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release and earnings presentation but are not disclosed in the filing text itself.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in this document. The filing solely announces the availability of the Q2 2022 results.
Guidance, Outlook, and Risks
Management Commentary: The company released an earnings presentation (Exhibit 99.2) which likely contains management commentary, guidance, and outlook, but the content of this presentation is not included in the text provided.
Risks and Contingencies: No specific risks or contingencies are described in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2022 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Earnings Presentation) for forward-looking guidance, pipeline updates, and liquidity runway.
- Verify the company's cash burn rate and funding status given the biopharmaceutical sector context.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibits.